How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ? (https://www.myeloma.org/videos/how-do-two-approaches-treating-high-risk-smoldering-multiple-myeloma-hrsmm-patients-differ)
|
In this week’s video, Dr. Brian G.M. Durie compares two trials that treat high-risk smoldering multiple myeloma — the CESAR trial and the CENTAURUS trial. BOTTOM LINE: The IMF’s Black Swan Research Initiative is excited about the CESAR trial and will conduct future trials in hopes of achieving a cure for myeloma. |
Ask a Question
Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (mailto:[email protected]) (Please do not send email attachments or lab reports.).
Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.